Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) Shares Outstanding (Weighted Average) (2020 - 2025)

Biofrontera (BFRI) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $9.7 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 100.17% year-over-year to $9.7 million; the TTM value through Sep 2025 reached $9.7 million, up 100.17%, while the annual FY2024 figure was $5.5 million, 256.74% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $9.7 million in Q3 2025 per BFRI's latest filing, up from $9.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $17.1 million in Q1 2022 and bottomed at $941175.0 in Q2 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $5.5 million, with a median of $4.8 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 799900.0% in 2021, then tumbled 92.2% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $8.8 million in 2021, then crashed by 88.0% to $1.1 million in 2022, then soared by 46.29% to $1.5 million in 2023, then skyrocketed by 256.74% to $5.5 million in 2024, then soared by 75.38% to $9.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $9.7 million in Q3 2025, $9.1 million in Q2 2025, and $8.9 million in Q1 2025.